Navigation Links
EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/-- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical results for MKC-1, its novel cell cycle inhibitor. The data were presented by EntreMed scientists at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis. These effects are consistent with mechanisms resulting from MKC-1 binding to multiple intracellular targets, including tubulin and the importin-beta proteins. The importin-beta family of proteins plays a critical role in nuclear transport and cell division.

In these studies, MKC-1 showed potent, dose-dependent activity against a variety of cell lines derived from cancers of human blood cells, and inhibited growth of primary cells derived from acute and chronic myelogenous leukemia (AML and CML) patients in vitro. MKC-1 was also shown to inhibit PI3-Kinase and mTOR pathways by inducing a dose-dependent reduction in the levels of the activated forms of the oncogenic kinases Akt and p70S6K. These signaling pathways are strongly linked to cancer proliferation and survival.

Additionally, MKC-1 showed enhanced activity with cytosine arabinoside (Ara-C) in combination studies in vitro when added either simultaneously or sequenti
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
5. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/28/2008)...APOLIS, Nov. 28 Eli Lill...pplemental New Drug Application (sNDA) from,the U...a(R) (duloxetine HCl),for the management of chron...n,the first half of 2009, adding data from a rece...hritis pain of the knee. , The decision doe...
(Date:11/26/2008)...sed information density, automation and intelligen...n ultrasound to an all new level , , CHICAG...s Healthcare ( www.siemens.com/healthcare ) hi...ume Scanner (ABVS)(1), the world,s first multi-us...he 94th Scientific Assembly and Annual Meeting of ...
(Date:11/25/2008)...ILLE, Ky., Nov. 25 Klei...eons performed the fifth U.S. hand transplant on M... Louisville,s Jewish Hospital Hand Care Center on ...an around noon and was completed shortly after 9 p...ttp://www.newscom.com/cgi-bin/prnh/20081125/DC4855...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 1VIE Healthcare Expands Its Operations in the Midwest and Obtains First Local Client 14637 2CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 1CVS Caremark Corp to Pay 2436 7 Million to U S 23 States 26 D C to Settle Medicaid Prescription Drug Fraud Allegations 14636 2AUDIO from Medialink and Kelloggs 3A A Blissful Way to Recommit to Your Resolution 14634 1New Foam Treatment for Varicose Veins 14633 1New Foam Treatment for Varicose Veins 14633 2
...re/ -- Accera, Inc.,today is presenting data from ...trial of AC-1202 (Ketasyn) in Alzheimer,s disease ...l Conference on,Prevention of Dementia in Washingt...linical and preclinical studies, AC-1202 was,shown...y and,cognition of subjects of a particular pharma...
...2007 - Critical,Therapeutics, Inc. (Nasdaq: CRTX) ...otal Phase III clinical trial of ZYFLO CR(TM),(zil...ssue of the,Journal of Asthma. ZYFLO CR was approv...on May 30, 2007. Critical Therapeutics,together w...cts to,begin marketing ZYFLO CR in the U.S. in the...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:12/2/2008)... ORLANDO, Fla., Dec. 2 MEDai, Inc...care solutions provider, has added a new module,t...ons. The new stand-alone,module monitors a popul...delines and alerts stakeholders when there has bee...e Risk Navigator Guidelines(TM) provides,real-tim...
(Date:12/2/2008)... CHICAGO, Dec. 2 MedCommons annou...the EMC Open Systems Archive Solution for Healthca...lution for Healthcare,Organizations provides a mo...gregates and reconciles patient information, inclu...plications into a patient-centric archive. The,in...
(Date:12/2/2008)... VANCOUVER, Dec. 2 /PRNewswire-FirstCall/ - Respo...) announced the initiation of a clinical trial of ...yncytial Virus (RSV). Prospective data from the cl...ubmission to the U.S. Food and Drug Administration...et clearance of the 3M Rapid Detection RSV test fo...
(Date:12/2/2008)... At Least 10 New Cellular Therapies Will Launch O...cision Resources , , WALTHAM, Mass., Dec. 2...rld,s leading research and advisory firms for phar...ellular therapies drug market will experience robu...e, reaching $1.5 billion in 2017. According to the...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 2Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 3Health News:Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial 4Health News:Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017 2
... from LaTrobe University of Australia have found a...ciparum, the parasite responsible for causing mala...imaquine for treatment // helps in killing P. falc...ne drug. Chloroquine is a largely used drug in the...
...avoidance is the only way to prevent food allergy,...ions. Although an individual could be allergic to ...he following // eight foods i.e. cow’s milk, egg, ...ellfish, legumes (peanut and soy), cereals (wheat,...
...ne of the most common breathing problems encounter..., there has been a considerable increase in the in...n. // It has been estimated that nearly 196,000 ch...States every year with asthma attacks. A considera...
...atent rows over basmati and turmeric, India doesn'... certainly not when it comes to its ancient healin...task force appointed by the government for protect...tual property is fast completing the documentation...
Other Medicine News:Health News:Improved parent-physician communication to prevent hospitalizations for childhood asthma 2Health News:Yoga, ayurveda being documented to stop patent misuse 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: